Kinases as Therapeutic Targets for Endometriosis
激酶作为子宫内膜异位症的治疗靶点
基本信息
- 批准号:10532966
- 负责人:
- 金额:$ 68.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-01 至 2027-04-30
- 项目状态:未结题
- 来源:
- 关键词:AMHR2 geneAddressAffectAffinityApoptosisBMPR2 geneBar CodesBindingCSF1R geneCell LineCellsCellular biologyChemicalsChemistryClinicalCollectionDNADataData SetDiseaseDysmenorrheaDyspareuniaEPHA2 geneEndocrineEndometriumFDA approvedFamilyFoundationsGene ExpressionGeneticGenomeGrantGrowthGynecologicHealthHormone AntagonistsHormonesHuman GenomeIRAK3 geneImmunologistIn VitroIncidenceInfertilityInflammationInflammatoryLeadLesionLibrariesMAP3K8 geneMYLK geneMediatingMedicineMenorrhagiaMetabolicMethodsMolecularNTRK2 geneNUAK1 geneNational Institute of Child Health and Human DevelopmentOrganoidsOvarian Clear Cell TumorOvarian EndometriosisPainPaperPathogenesisPathologicPathway interactionsPatientsPeritonealPharmaceutical PreparationsPharmacologic SubstancePhosphotransferasesPhysiologicalPromegaProtein KinaseProteinsPublishingRecombinantsRoleSequential TreatmentSmall Interfering RNAStromal CellsSyndromeSystemTGFBR2 geneTechnologyTestingTherapeuticTherapeutic AgentsTissuesTransforming Growth Factor betaValidationWomanWomen&aposs HealthWorkbasecollegedrug discoveryefficacious treatmentendometrial organoidendometriosisexperiencein vivoin vivo Modelinhibitorinterestkinase inhibitorknock-downmouse modelmultidisciplinarynew therapeutic targetnovelnovel therapeuticsoverexpressionpatient populationpre-clinicalpublic health relevancereceptorreproductivescreeningsmall moleculesmall molecule inhibitortherapeutic targetweb portal
项目摘要
ABSTRACT
The human genome encodes 538 protein kinases, most of which are functionally important and are involved in
the pathogenesis of many diseases. This new R01 is a discovery-based grant focused on the molecular
validation of novel kinases that are upregulated in endometriosis. To address new therapeutic options for
endometriosis, we will validate a subset of endometriosis-implicated kinases using siRNA knockdown
strategies and available small molecule inhibitors and subsequently use DNA-Encoded Chemistry Technology
(DEC-Tec) to identify novel therapeutic molecules for further chemical validation in vitro and in vivo. We
identified dozens of kinases that are statistically upregulated in the lesions of patients with ovarian
endometriosis, peritoneal endometriosis, and/or deep infiltrating endometriosis compared to control and patient
endometrium. The hypothesis for this R01 is that inhibition of one or more of these novel kinase targets will be
effective in the treatment of endometriosis. In this proposal, we outline a comprehensive approach to
functionally characterize and target kinases in primary endometriotic stromal cells and organoid cultures
derived from women. In parallel, we will utilize state-of-the-art DEC-Tec selection methods available in the
Center for Drug Discovery (CDD) at Baylor College of Medicine (BCM) to identify novel kinase inhibitors that
will then be re-synthesized without the DNA barcode and chemically optimized by our team. We currently have
a screening collection of over 6 billion DNA-encoded molecules. The overarching objective is to identify potent
and selective kinase inhibitors that can provide a foundation for new medicines to address the unmet clinical
needs of endometriosis patients. The Specific Aims are: 1) Perform target validation of overexpressed kinases;
2) Use DEC-Tec to identify novel small-molecule inhibitors of validated kinases and optimize the selectivity,
activity, and stability of high affinity kinase binders; and 3) Evaluate optimized high affinity kinase inhibitors in
vitro and in vivo. Identifying new efficacious therapies for endometriosis requires a multifaceted approach that
necessitates increased efforts to identify and screen novel targets for drug discovery. Our approach, which
combines gene expression datasets for target identification with a novel DEC-Tec drug discovery platform, will
rapidly advance key kinase targets through a well-established drug discovery pipeline. Our multidisciplinary
team is seeking to discover new chemical entities that address the non-hormonal axes of endometriosis as
stand-alone therapy or as sequential therapy during hiatus from endocrine-suppressing agents. Our DEC-Tec
platform will help us to find the first specific inhibitors of unexplored kinases (a major druggable class of
proteins) that are elevated in endometriosis to dissect these key physiological pathways and pathological
mechanisms underlying endometriosis and provide new disease-specific treatment options.
摘要
人类基因组编码538个蛋白激酶,其中大部分在功能上是重要的,并参与
许多疾病的发病机制。这一新的R01是一项基于发现的拨款,专注于分子
子宫内膜异位症中上调的新蛋白激酶的验证。解决新的治疗方案
子宫内膜异位症,我们将使用siRNA敲除来验证与子宫内膜异位症相关的激酶的子集
策略和可用的小分子抑制剂,并随后使用DNA编码的化学技术
(DEC-Tec),以确定新的治疗分子,以便在体外和体内进一步进行化学验证。我们
确定了数十种在卵巢疾病患者皮损中统计上上调的蛋白激酶
子宫内膜异位症、腹膜子宫内膜异位症和/或深度浸润性子宫内膜异位症与对照组和患者的比较
子宫内膜。R01的假设是,抑制一个或多个这些新的激酶靶点将是
对治疗子宫内膜异位症有效。在这项提案中,我们概述了一种全面的方法来
原代子宫内膜异位间质细胞和器质性培养中的功能特征和靶向蛋白激酶
源自女性。同时,我们将利用最先进的DEC-Tec选择方法,可在
位于贝勒医学院(BCM)的药物发现中心(CDD),以确定可
然后在没有DNA条形码的情况下重新合成,并由我们的团队进行化学优化。我们目前有
超过60亿个DNA编码分子的筛选集合。首要目标是找出有效的
和选择性的激酶抑制剂,可以为解决未满足的临床问题的新药提供基础
子宫内膜异位症患者的需求。其具体目标是:1)对过表达的激酶进行靶向验证;
2)使用DEC-Tec来鉴定新的有效的激酶的小分子抑制剂并优化选择性,
高亲和力激酶结合剂的活性和稳定性;以及3)评估优化的高亲和力激酶抑制剂
体外和体内。寻找治疗子宫内膜异位症的新的有效疗法需要多方面的方法,
需要加大努力来确定和筛选药物发现的新靶点。我们的方法,即
将用于靶标识别的基因表达数据集与新型DEC-Tec药物发现平台相结合,Will
通过完善的药物发现管道快速推进关键的激酶靶点。我们的多学科
研究小组正在寻求发现新的化学实体来解决子宫内膜异位症的非激素轴,如
在间歇期单独治疗或作为内分泌抑制药的序贯治疗。我们的DEC-Tec
Platform将帮助我们找到第一种未探索的激酶的特定抑制剂(一种主要的可用药类别
蛋白质)在子宫内膜异位症中升高,以剖析这些关键的生理途径和病理
研究子宫内膜异位症的潜在机制,并提供新的针对疾病的治疗方案。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARTIN M. MATZUK其他文献
MARTIN M. MATZUK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARTIN M. MATZUK', 18)}}的其他基金
Kinases as Therapeutic Targets for Endometriosis
激酶作为子宫内膜异位症的治疗靶点
- 批准号:
10674987 - 财政年份:2022
- 资助金额:
$ 68.77万 - 项目类别:
Disruption of semen liquefaction using specific KLK3 inhibitors as a new contraceptive
使用特定 KLK3 抑制剂作为新避孕药破坏精液液化
- 批准号:
10682061 - 财政年份:2022
- 资助金额:
$ 68.77万 - 项目类别:
Disruption of semen liquefaction using specific KLK3 inhibitors as a new contraceptive
使用特定 KLK3 抑制剂作为新避孕药破坏精液液化
- 批准号:
10764639 - 财政年份:2022
- 资助金额:
$ 68.77万 - 项目类别:
Disruption of semen liquefaction using specific KLK3 inhibitors as a new contraceptive
使用特定 KLK3 抑制剂作为新避孕药破坏精液液化
- 批准号:
10419647 - 财政年份:2022
- 资助金额:
$ 68.77万 - 项目类别:
Disruption of semen liquefaction using specific KLK3 inhibitors as a new contraceptive
使用特定 KLK3 抑制剂作为新避孕药破坏精液液化
- 批准号:
10598585 - 财政年份:2022
- 资助金额:
$ 68.77万 - 项目类别:
Targeting testis-specific ubiquitin-proteasome pathways for male contraception
针对男性避孕的睾丸特异性泛素蛋白酶体途径
- 批准号:
10018522 - 财政年份:2019
- 资助金额:
$ 68.77万 - 项目类别:
Functional genomics and DEC-Tec to identify germ cell-specific contraceptives
功能基因组学和 DEC-Tec 鉴定生殖细胞特异性避孕药
- 批准号:
10164823 - 财政年份:2017
- 资助金额:
$ 68.77万 - 项目类别:
Targeting sperm-specific proteins during meiosis and sperm morphogenesis
在减数分裂和精子形态发生过程中靶向精子特异性蛋白
- 批准号:
10164826 - 财政年份:2017
- 资助金额:
$ 68.77万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 68.77万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 68.77万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 68.77万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 68.77万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 68.77万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 68.77万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 68.77万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 68.77万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 68.77万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 68.77万 - 项目类别:
Research Grant